News | January 13, 2025
Apotex acquires US rights to PROVIGIL and NUVIGIL
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
Dr. Smith brings 30 years of clinical and translational research experience in obesity, diabetes, and metabolism with over 300 scientific publications
Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)
Investment will fund expansion to meet rising demand for CRDMO services
This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t
Acquisition expands high-value medical platform
These initiatives will strengthen the company’s capital base, providing financial flexibility for future
Consequent to this appointment, Sarosh Shetty ceases to be Interim CEO of ICH.
These three NDAs of Sitagliptin (base) and combination franchise have been approved by the USFDA earlier through the 505(b)(2) route
The new brand name reflects the evolution from a generics-focused Contract Research Organization (CRO) to a drug development services enterprise
Subscribe To Our Newsletter & Stay Updated
